NCT04183660招募中不适用
A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System for Cardiac and Respiratory Support: The MOBYBOX Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 4
- 主要终点
- Rates of device and procedure related serious adverse events
研究概览
简要总结
The purpose of this study is to evaluate prospectively the safety and performance of the MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure or in the veno-venous configuration in patients with severe respiratory failure.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with cardiac, respiratory or cardiorespiratory failure or imminent failure and 1 of the 5 following sets of findings:
- •A Murray score ≥ 3.0 and/or severe hypoxemia with A PaO2/FIO2 > 100 mm on 0.9 FIO2;
- •Uncompensated hypercapnia with pH <7.2 despite a Pplateau > 30 cm H20;
- •Significant air leak/bronchopleural fistula;
- •Need for intubation in a patient on lung transplant list;
- •Immediate/risk of cardiac or respiratory collapse (pulmonary embolus, blocked airway, blocked blood flow, unresponsive to optimal care);
- •Written consent of the patient or the legal guardian or external consulting physician as designated and approved by the Ethics Committee.
排除标准
- •High pressure ventilation (FIO2 > 0.9 and Pplateau > 30 cm H2O) or high FIO2 requirements for more than 7 days;
- •Severe intracranial bleeding, which precludes the use of anticoagulation therapy or any other inability to be anticoagulated
- •Excessive weight (> 180 Kg)
- •Severe irreversible brain injury (e.g., hypoxic brain injury)
- •Inability to accept blood products;
- •Any condition or organ dysfunction that would limit the likelihood of overall benefit from ECMO, such as severe, irreversible brain injury, hepatic and/or renal failure, or untreatable metastatic cancer;
- •Immunosuppression with an absolute neutrophil count < 400/mm3;
- •Patient has been treated with ECMO ≤ 48 hours.
- •For veno-veno ECMO in the setting of respiratory failure the following exclusion criteria apply:
- •Severe pulmonary hypertension (mPAP > 50 mm Hg)
- •Severe right or left sided heart failure (EF < 25%)
- •For veno-arterial ECMO in the setting of cardiac insufficiency:
- •Severe aortic regurgitation
- •Aortic dissection.
- •The patient is moribund, or the patient has severe or deteriorating damage in critical body systems.
- •Patient is participating in an investigational drug or device study trial that has not reached the primary endpoint or that interferes with the current study endpoints.
- •Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.
结局指标
主要结局
Rates of device and procedure related serious adverse events
时间窗: 24 hours
Acute safety defined as rates of device and procedure related serious adverse events up to 24 hours post-intervention.
次要结局
- Adverse Event rate(24 hours)
- Mortality rate(30 days)
- Device performance success(every 4 hours while the patient receives ECMO using the MOBYBOX device)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical ExcisionEarlobe KeloidsNCT01706861Halscion, Inc.51
已完成
不适用
Study of the Hummingbird TTS™ Tympanostomy Tube SystemOtitis MediaNCT03503591Preceptis Medical, Inc.109
已完成
不适用
Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a WoundScarNCT01706848Halscion, Inc.60
已完成
不适用
Toviaz Post Marketing Surveillance StudyOveractive BladderNCT00879398Pfizer3,000
撤回
不适用
Registry Study for the Use of HEMOBLAST™ Bellows in AbdominoplastyAbdominoplastyNCT03770195Biom'Up France SAS